EGFR and KRAS Mutations in ALK-Positive Lung Adenocarcinomas: Biological and Clinical Effect

Clinical Lung Cancer

Volumn 17, Issue 1, 2016, Pages 56-61

  Sahnane, Nora ^a   Frattini, Milo ^b   Bernasconi, Barbara ^a   Zappa, Francesco ^c   Schiavone, Giovanna ^d   Wannesson, Luciano ^d   Antonelli, Paola ^e   Balzarini, Piera ^f   Sessa, Fausto ^a   Mazzucchelli, Luca ^b   Tibiletti, Maria Grazia ^g   Martin, Vittoria ^b  

^a UNIVERSITY OF INSUBRIA   (Italy)

^b INSTITUTE OF PATHOLOGY   (Switzerland)

^c Reparto di Chirurgia Ortopedica   (Switzerland)

^d ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND   (Switzerland)

^e BUSTO ARSIZIO HOSPITAL   (Italy)

^f UNIVERSITY OF BRESCIA   (Italy)

^g OSPEDALE DI CIRCOLO   (Italy)

Author keywords

ALK rearrangements; Crizotinib; EGFR mutations; Erlotinib; KRAS mutations

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; ANTINEOPLASTIC METAL COMPLEX; CARBOPLATINUM; CERITINIB; CISPLATIN; CRIZOTINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEMCITABINE; PEMETREXED; UNCLASSIFIED DRUG; EGFR PROTEIN, HUMAN; KRAS PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; PROTEIN P21; PROTEIN TYROSINE KINASE; TUMOR MARKER;

ADULT; ADVANCED CANCER; AGED; ALLELE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER LOCALIZATION; CANCER MORTALITY; CANCER REGRESSION; CANCER STAGING; CHROMOSOME 12; CLINICAL ARTICLE; CLINICAL EVALUATION; CODON; COMPARATIVE EFFECTIVENESS; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERANCE; DRUG TREATMENT FAILURE; EXON; FATIGUE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE DOSAGE; GENE MUTATION; GENE REARRANGEMENT; HUMAN; HUMAN TISSUE; INCIDENCE; LIVER METASTASIS; LUNG ADENOCARCINOMA; LUNG LESION; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; MEDIASTINUM METASTASIS; MEDICATION COMPLIANCE; MIDDLE AGED; MISSENSE MUTATION; MOLECULARLY TARGETED THERAPY; MULTIPLE CYCLE TREATMENT; MUTATIONAL ANALYSIS; ONCOGENE K RAS; PATIENT COMPLIANCE; PYROSEQUENCING; SHOULDER PAIN; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VERY ELDERLY; ADENOCARCINOMA; CARCINOMA, NON-SMALL-CELL LUNG; COPY NUMBER VARIATION; FOLLOW UP; GENETICS; LUNG NEOPLASMS; METABOLISM; MUTATION; PATHOLOGY; PROGNOSIS;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; CARCINOMA, NON-SMALL-CELL LUNG; DNA COPY NUMBER VARIATIONS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; PROGNOSIS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS P21(RAS); RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84953356845     PISSN: 15257304     EISSN: 19380690     Source Type: Journal    
DOI: 10.1016/j.cllc.2015.08.001     Document Type: Article

References (34)

1. N.I. Lindeman, P.T. Cagle, M.B. Beasley, and et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology J Mol Diagn 15 2013 415 453
2. S. Rothschild, A. Zippeliusa, D.C. Betticher, and et al. New therapeutic concepts in bronchial carcinoma. Oncogenic mechanisms and molecular markers, [in German] Schweiz Med Forum 11 2011 941 947
3. Nowak F, Calvo F, Soria JC. Europe does it better: molecular testing across a national health care system - the French Example. ASCO 2013 Educational Book. 2013, American Society of Clinical Oncology; Chicago, IL, 332-337.
4. Clinicaltrials.gov [Web site]. A clinical trial testing the efficacy of crizotinib versus standard chemotherapy pemetrexed plus cisplatin or carboplatin in patients with ALK positive non squamous cancer of the lung. Available at: http://clinicaltrials.gov/ct2/show/NCT01154140. Accessed June 2011.
5. J.F. Gainor, A.M. Varghese, S.H. Ou, and et al. ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1683 patients with non-small-cell lung cancer Clin Cancer Res 19 2013 4273 4281
6. Cancer Genome Atlas Research Network Comprehensive molecular profiling of lung adenocarcinoma [published erratum apears in: Nature 2014; 514:262] Nature 511 2014 543 550
7. J.P. Koivunen, C. Mermel, K. Zejnullahu, and et al. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer Clin Cancer Res 14 2008 4275 4283
8. J.J. Yang, X.C. Zhang, J. Su, and et al. Lung cancers with concomitant EGFR mutations and ALK rearrangements: diverse responses to EGFR-TKI and crizotinib in relation to diverse receptors phosphorylation Clin Cancer Res 20 2014 1383 1392
9. H. Sasaki, Y. Hikosaka, O. Kawano, S. Moriyama, M. Yano, and Y. Fujii Evaluation of Kras gene mutation and copy number gain in non-small-cell lung cancer J Thorac Oncol 6 2011 15 20
10. T. Sasaki, J. Koivunen, A. Ogino, and et al. A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors Cancer Res 71 2011 6051 6060
11. J.K. Lee, T.M. Kim, Y. Koh, and et al. Differential sensitivities to tyrosine kinase inhibitors in NSCLC harboring EGFR mutation and ALK translocation Lung Cancer 77 2012 460 463
12. G. Rossi, L. Baldi, F. Barbieri, F. Bertolini, and M. Tiseo Concomitant EGFR and KRAS mutations in ALK rearranged lung cancer Ann Oncol 26 2015 1035 1036
13. L. Baldi, M.C. Mengoli, A. Bisagni, M.C. Banzi, C. Boni, and G. Rossi Concomitant EGFR mutation and ALK rearrangement in lung adenocarcinoma is more frequent than expected: report of a case and review of the literature with demonstration of genes alteration into the same tumor cells Lung Cancer 86 2014 291 295
14. J.K. Won, B. Keam, J. Koh, and et al. Concomitant ALK translocation and EGFR mutation in lung cancer: a comparison of direct sequencing and sensitive assays and the impact on responsiveness to tyrosine kinase inhibitor Ann Oncol 26 2015 348 354
15. A.T. Shaw, B.Y. Yeap, M. Mino-Kenudson, and et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK J Clin Oncol 27 2009 4247 4253
16. V. Martin, B. Bernasconi, E. Merlo, and et al. ALK testing in lung adenocarcinoma: technical aspects to improve FISH evaluation in daily practice J Thorac Oncol 10 2014 595 602
17. Hastings RJ, Bown N, Tibiletti MG, et al. Guidelines for cytogenetic investigations in tumours. Eur J Hum Genet, Published online March 25, 2015; http://dx.doi.org/10.1038/ejhg.2015.35.
18. W. Pao, V. Miller, M. Zakowski, and et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib Proc Natl Acad Sci U S A 101 2004 13306 13311
19. N. Sahnane, R. Gueli, M.G. Tibiletti, and et al. Pyrosequencing for EGFR mutation detection: diagnostic accuracy and clinical implications Diagn Mol Pathol 22 2013 196 203
20. M. Frattini, P. Saletti, E. Romagnani, and et al. PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients Br J Cancer 97 2007 1139 1145
21. N. Sahnane, D. Furlan, M. Monti, and et al. Microsatellite unstable gastrointestinal neuroendocrine carcinomas: a new clinicopathologic entity Endocr Relat Cancer 22 2014 35 45
22. V. Martin, L. Mazzucchelli, and M. Frattini An overview of the epidermal growth factor receptor fluorescence in situ hybridisation challenge in tumour pathology J Clin Pathol 62 2009 314 324
23. W.D. Travis, E. Brambilla, M. Noguchi, and et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society: international multidisciplinary classification of lung adenocarcinoma: executive summary Proc Am Thorac Soc 8 2011 381 385
24. R. Rosell, E. Carcereny, R. Gervais, and et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial Lancet Oncol 13 2012 239 246
25. A.T. Shaw, D.W. Kim, K. Nakagawa, and et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer N Engl J Med 368 2013 2385 2394
26. E.A. Eisenhauer, P. Therasse, J. Bogaerts, and et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer 45 2009 228 247
27. N.B. Leighl, N. Rekhtman, W.A. Biermann, and et al. Molecular testing for selection of patients with lung cancer for epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors: American Society of Clinical Oncology endorsement of the College of American Pathologists/International Association for the study of lung cancer/association for molecular pathology guideline J Clin Oncol 32 2014 3673 3679
28. X. Zhang, S. Zhang, X. Yang, and et al. Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression Mol Cancer 9 2010 188
29. J. Soh, N. Okumura, W.W. Lockwood, and et al. Oncogene mutations, copy number gains and mutant allele specific imbalance (MASI) frequently occur together in tumor cells PLoS One 4 2009 e7464
30. S.I. Chiosea, C.K. Sherer, T. Jelic, and S. Dacic KRAS mutant allele-specific imbalance in lung adenocarcinoma Mod Pathol 24 2011 1571 1577
31. T.J. Kim, C.K. Park, C.D. Yeo, and et al. Simultaneous diagnostic platform of genotyping EGFR, KRAS, and ALK in 510 Korean patients with non-small-cell lung cancer highlights significantly higher ALK rearrangement rate in advanced stage J Surg Oncol 110 2014 245 251
32. H. Tanaka, A. Hayashi, T. Morimoto, and et al. A case of lung adenocarcinoma harboring EGFR mutation and EML4-ALK fusion gene BMC Cancer 12 2012 558
33. R. Chiari, S. Duranti, V. Ludovini, and et al. Long-term response to gefitinib and crizotinib in lung adenocarcinoma harboring both epidermal growth factor receptor mutation and EML4-ALK fusion gene J Clin Oncol 32 2014 e30 e32
34. S. Campos-Gomez, H. Lara-Guerra, M.J. Routbort, X. Lu, and G.R. Simon Lung adenocarcinoma with concurrent KRAS mutation and ALK rearrangement responding to crizotinib: case report Int J Biol Markers 30 2015 e254 e257